REC: CardioClinics最新文献

Mitral regurgitant volume quantification. Time to reconsider PISA? 二尖瓣返流量定量。是时候重新考虑PISA了？

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2024.12.004

Chiara Pidone , Lorenzo Niro , Claudia Escabia Riera , Elena Ferrer-Sistach

引用次数: 0

Levosimendán ambulatorio intermitente en pacientes ancianos con insuficiencia cardiaca avanzada: registro LEVO-D 晚期心力衰竭老年患者间歇性左旋西门丹：LEVO-D记录

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.03.002

Carla Iglesias Otero , David Dobarro Pérez , Carlos Rodríguez Pascual , Javier de Juan Bagudá , Fernando de Frutos Seminario , José González Costello , en representación de los miembros del registro español LEVO-D

{"title":"Levosimendán ambulatorio intermitente en pacientes ancianos con insuficiencia cardiaca avanzada: registro LEVO-D","authors":"Carla Iglesias Otero , David Dobarro Pérez , Carlos Rodríguez Pascual , Javier de Juan Bagudá , Fernando de Frutos Seminario , José González Costello , en representación de los miembros del registro español LEVO-D","doi":"10.1016/j.rccl.2025.03.002","DOIUrl":"10.1016/j.rccl.2025.03.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Elderly patients with advanced heart failure (AHF) who are not candidates for advanced treatments have a poor prognosis. The objective of this study is to describe patterns of use and safety of intermittent ambulatory infusion of levosimendan in patients older than 75years with AHF as a treatment option, compared to patients younger than 75years.</div></div><div><h3>Methods</h3><div>A multicenter retrospective analysis was performed involving 23 tertiary hospitals (January 2015-September 2020). A total of 404 patients were enrolled (37% older than 75years and 63% younger than 75years). Patients had to be on optimal medical treatment. Patients with onset heart failure (HF) or patients undergoing any procedure that would improve prognosis after starting levosimendan were excluded.</div></div><div><h3>Results</h3><div>A Cox regression model showed that 1-year response (defined as absence of death, HF admission, or unplanned HF visit) did not differ between patients. Levosimendan administration had to be discontinued more frequently in patients older than 75years due to lack of efficacy and side effects (40.7% discontinued), but this was not associated with an increase in implantable cardioverter-defibrillator therapy 1year before and 1year after drug administration.</div></div><div><h3>Conclusions</h3><div>The LEVO-D registry adds information to the current limited scientific evidence on the prognosis of elderly patients with AHF and suggests that levosimendan is a safe option that can reduce readmissions and emergency visits for HF.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 3","pages":"Pages 204-212"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Papel del ecógrafo de bolsillo en la exploración cardiovascular multidisciplinar. Revisión del estado actual 袖珍超声在多学科心血管扫描中的作用。当前状态检查

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.04.002

Diego Segura-Rodríguez , Clara Bonanad , Elena Fortuny , Ángel Prades-Sánchez , Román Freixa-Pamias , Sergio Raposeiras-Roubín , David Vivas Balcones

引用次数: 0

Bridging the gap: Addressing anticoagulation underutilization in elderly atrial fibrillation patients post-fall 弥合差距：解决老年房颤患者跌倒后抗凝使用不足的问题

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.02.003

Musa Bin Bashir , Jeyasundar Dhevenbu , Zhi Quan Wang

{"title":"Bridging the gap: Addressing anticoagulation underutilization in elderly atrial fibrillation patients post-fall","authors":"Musa Bin Bashir , Jeyasundar Dhevenbu , Zhi Quan Wang","doi":"10.1016/j.rccl.2025.02.003","DOIUrl":"10.1016/j.rccl.2025.02.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The choice to start or stop anticoagulation therapy in elderly patients post-fall is a major clinical challenge because falls increase the risk of bleeding. However, anticoagulation is essential in patients with atrial fibrillation (AF) to prevent thromboembolic events, and concerns about bleeding and bias may result in the prescription of anticoagulants. This study, conducted from September 2019 to October 2023, examined patients aged>50 years with AF who fell in-hospital, with the aim of identifying influencing anticoagulant prescriptions.</div></div><div><h3>Methods</h3><div>All the patients included in the study experienced falls during hospitalization. It is important to note that these falls were not a reason for admission.</div></div><div><h3>Results</h3><div>Out of the 327 patients in the study, 210 (64.2%) were discharged on anticoagulation therapy, and 79.5% received non-vitamin K antagonist oral anticoagulants. Significant associations were found between cardiology consultations and male participants (<em>P</em>  <.001), and those with health insurance (<em>P</em>  <.001), rural residence (<em>P</em>  <.001), and health insurance (<em>P</em>  <!-->.001) were significantly associated with anticoagulation discharge.</div></div><div><h3>Conclusions</h3><div>Contrary to expectations, the decision to initiate oral anticoagulation in hospitalized patients with AF and a history of accidental falls was not primarily based on risk scales such as CHA<sub>2</sub>DS<sub>2</sub>-VASc but rather on other clinical, social, and medical coverage conditions. This underscores the need for a more nuanced understanding of the factors influencing anticoagulation decisions in this vulnerable population.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 3","pages":"Pages 185-192"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chloroquine and hydroxychloroquine induced cardiomyopathy: A systematic review of literature 氯喹和羟氯喹引起的心肌病：文献系统综述

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.01.011

Vanda Devesa Neto , João Gouveia Fiúza , Inês Pires , Luís Ferreira Santos , António Costa

{"title":"Chloroquine and hydroxychloroquine induced cardiomyopathy: A systematic review of literature","authors":"Vanda Devesa Neto , João Gouveia Fiúza , Inês Pires , Luís Ferreira Santos , António Costa","doi":"10.1016/j.rccl.2025.01.011","DOIUrl":"10.1016/j.rccl.2025.01.011","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Chloroquine (CQ) and hydroxychloroquine (HCQ), initially developed for malaria prophylaxis, are now widely used in rheumatic diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Despite their therapeutic benefits, these drugs can induce cardiotoxicity, particularly cardiomyopathy. This systematic review evaluates the prevalence, clinical features, and diagnostic challenges of CQ/HCQ-induced cardiomyopathy.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted in PubMed, EMBASE, and Cochrane databases, identifying 60 studies reporting 79 cases of CQ/HCQ-induced cardiomyopathy. Inclusion criteria required histopathological confirmation via endomyocardial biopsy. Data on clinical presentations, diagnostic findings, and outcomes were extracted and analyzed.</div></div><div><h3>Results</h3><div>Patients were predominantly female (76%), with a median age of 56 years. The cardiomyopathies observed included hypertrophic, dilated, and restrictive forms, frequently presenting with heart failure and conduction disorders, such as atrioventricular block and arrhythmias. Cardiac magnetic resonance imaging and endomyocardial biopsy revealed characteristic toxicological changes, including myocyte vacuolization and fibrosis. Management often involved discontinuation of therapy, but severe cases progressed to cardiac transplantation or resulted in mortality (19%).</div></div><div><h3>Conclusions</h3><div>CQ/HCQ-induced cardiomyopathy is an underrecognized complication with significant morbidity and mortality. Early detection through continuous cardiac monitoring in patients on long-term CQ/HCQ therapy is crucial. Effective management, including timely drug discontinuation, may improve outcomes, although prognosis remains guarded in advanced stages.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 3","pages":"Pages 193-203"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary artery calcium score in patients with non-ST-segment elevation acute coronary syndrome 非st段抬高急性冠状动脉综合征患者冠状动脉钙评分

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.02.002

Samuel Del Castillo García, Ignacio Iglesias Gárriz, Carmen Garrote Coloma, Javier Vara Manso, José Félix Corral Fernández, David Alonso Rodríguez, Felipe Fernández Vázquez

{"title":"Coronary artery calcium score in patients with non-ST-segment elevation acute coronary syndrome","authors":"Samuel Del Castillo García, Ignacio Iglesias Gárriz, Carmen Garrote Coloma, Javier Vara Manso, José Félix Corral Fernández, David Alonso Rodríguez, Felipe Fernández Vázquez","doi":"10.1016/j.rccl.2025.02.002","DOIUrl":"10.1016/j.rccl.2025.02.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Coronary artery calcium (CAC) score is a marker of coronary atherosclerotic burden and can provide diagnostic and prognostic information in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). This study aims to evaluate the relationship between CAC and the need for revascularization in patients with NSTEACS.</div></div><div><h3>Methods</h3><div>We included prospectively 276 patients aged ≥18 years admitted with NSTEACS. A computed tomography was performed to measure CAC, categorized into groups: 0 Agatston units (AU), 1–100AU, 101–400AU, and >400AU. All patients underwent invasive coronary angiography.</div></div><div><h3>Results</h3><div>The median CAC score was 221AU. A total of 62.7% of patients underwent revascularization; the proportion of revascularization increased with CAC, with 25% in the CAC=0 group and 83.3% in the high CAC (>400AU) group. The CAC score demonstrated a negative predictive value of 69.4% for ruling out significant stenosis.</div></div><div><h3>Conclusions</h3><div>The CAC score is significantly associated with the need for revascularization in patients with NSTEACS, highlighting the atherosclerotic burden and its potential in risk stratification and clinical decision-making.</div><div>.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 3","pages":"Pages 167-175"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcio coronario en el SCASEST: ¿una realidad hoy en día? SCASEST中的冠状动脉钙：今天的现实？

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.04.004

Javier Maíllo , Rocío Eiros , Candelas Pérez del Villar

引用次数: 0

Sofosbuvir and QT interval: A new chapter in the safety profile of direct-acting antivirals 索非布韦和QT间期：直接作用抗病毒药物安全性的新篇章

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.04.003

Carlos Minguito Carazo , Moisés Rodríguez Mañero

引用次数: 0

Electrocardiographic alterations during direct-acting antiviral therapy against hepatitis C virus 丙型肝炎病毒直接抗病毒治疗期间的心电图改变

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2025.02.004

Olga Neva López-García , Daniel García-Arribas , Carmen Olmos , María José Devesa Medina , Javier Higueras Nafría , Sonia Izquierdo Rubio , Francisca Cuenca Alarcón , Maite Maroto Castellanos , Ana Fernández-Vega , Alejandro Cruz-Utrilla , Pablo Martínez-Vives , Enrique Rey

{"title":"Electrocardiographic alterations during direct-acting antiviral therapy against hepatitis C virus","authors":"Olga Neva López-García , Daniel García-Arribas , Carmen Olmos , María José Devesa Medina , Javier Higueras Nafría , Sonia Izquierdo Rubio , Francisca Cuenca Alarcón , Maite Maroto Castellanos , Ana Fernández-Vega , Alejandro Cruz-Utrilla , Pablo Martínez-Vives , Enrique Rey","doi":"10.1016/j.rccl.2025.02.004","DOIUrl":"10.1016/j.rccl.2025.02.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>QTc interval alterations have been described in patients receiving sofosbuvir. Our objective was to evaluate the effect of anti-hepatitis C virus drugs on the human cardiac conduction system.</div></div><div><h3>Methods</h3><div>We included all patients with hepatitis C virus infection that started treatment with direct-acting antivirals in a tertiary hospital between May 2016 and March 2017. Three electrocardiograms were performed in them: before starting treatment; during treatment; and at least 3 weeks after finished treatment. Heart rate, PR, QRS, and QTc intervals were compared between patients with and without sofosbuvir. Patients were followed for a mean time of 41.9 weeks.</div></div><div><h3>Results</h3><div>A total of 101 patients were studied, 61 received treatment with sofosbuvir and 40 without sofosbuvir. No differences were found between the 2 groups regarding heart rate, and PR intervals. There was a statistically significant enlargement of QTc in patients with sofosbuvir at the fourth week of treatment (415.3ms vs 420.8ms) that returned to baseline values once finalized (411.1ms; <em>P</em>  <!-->.029). These differences were not observed in patients without sofosbuvir.</div></div><div><h3>Conclusions</h3><div>We observed a statistically significant prolongation of the QTc interval at the fourth week of treatment in patients with sofosbuvir, which returned to baseline levels once the treatment was finished. Further prospective studies are needed to assess the clinical relevance of these findings.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"60 3","pages":"Pages 176-184"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formación en cuidados intensivos cardiológicos: situación actual, modelos formativos y propuestas de mejora 心脏重症监护培训：现状、培训模式和改进建议

REC: CardioClinics Pub Date : 2025-07-01 DOI: 10.1016/j.rccl.2024.10.005

Pablo Legarra Oroquieta , David González Calle , Jordi Bañeras , Ana Hurtado Doce , Elena Collado Lledó

引用次数: 0